|
Online CME Activity
Recurrent Triple-Negative Breast Cancer: Therapeutic Options and Prognosis
|
NOTE: Although this activity is no longer certified for credit, we believe that it contains important information and hope you’ll review, print or email it to a colleague.
Recurrent Triple-Negative Breast Cancer: Therapeutic Options and Prognosis
1.00 AMA PRA Category 1 Credits™
Learning Objectives
Assess the prognostic and therapeutic significance of emerging evidence that the triple-negative breast cancer subtype has preferential sites of metastatic relapse, particularly the brain and viscera.
Accreditation
This educational program is conceived and credited in accordance with ACCME’s Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with Pri-Med Institute’s Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of Pri-Med Institute.
| Credits |
Type |
Accreditation Statement |
Designation Statement |
| 1.00 |
AMA PRA Category 1 Credits™ |
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
Pri-Med Institute designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
Faculty and Editorial Board
Written By:
Lisa A. Carey, MD, Associate Professor of Medicine, University of North Carolina Medical School; Medical Director, UNC Breast Center, University of North Carolina Lineberger Comprehensive Cancer Center
Edited By:
Kate Rouhana, MA, Pri-Med Institute
Financial Disclosure Statement(s)
Dr Cary receives research funding from Bristol-Myers Squibb, Genentech, Genomic, GlaxoSmithKline, and Novartis. She also is also an advisor to Eli Lilly, sanofi-aventis, Wyeth, and BiPar.
The content collaborators at Dana-Farber Cancer Institute have no financial relationships to disclose.
Ms Rouhana has no financial relationships to disclose.
Education Partner:
Dana-Farber Cancer Institute
Commercial Support:
Genentech BioOncology and sanofi-aventis
Instructions for Obtaining Credit:
Complete this activity. Answer the questions in the attached posttest and evaluation. Click on "claim credit" and follow the instructions to print out the credit certificate.
Computer System Requirements:
Internet Explorer (version 5.5 and above) is the recommended browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A minimum screen resolution setting of 800 x 600 is recommended. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.
Disclaimer
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, M|C Communications, LLC, or the Dana-Farber Cancer Institute.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
|
|
|